NEW YORK, NY--(Marketwire -03/02/12)- Biotechnology shares have been on impressive run of late. Led by the growing popularity in early stage biotechnology companies, the iShares Nasdaq Biotechnology Index Fund is up roughly 20 percent over the last three months. A recent survey from BIO Industry Analysis finds that investors are more focused on early stage companies than later. "And, this sentiment is also borne out by the increase in percentage of investors who indicate that they are willing to invest in small market cap biotechs," Alan Eisenberg, executive vice president of emerging companies and business development, explained. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Alimera Sciences, Inc. (NASDAQ: ALIM - News) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP - News). Access to the full company reports can be found at:
Biotech firms continue to negotiate a more challenging regulation process. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. Earlier this week the company announced the positive outcome of the Decentralized Procedure (DCP) for ILUVIEN in Europe. ILUVIEN is a sustained release intravitreal implant used to treat chronic diabetic macular edema (DME).
Chelsea Therapeutics International, Ltd., a development-stage pharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutic products for the treatment of various human diseases. Shares of the company skyrocketed last week after an FDA advisory panel said Chelsea's hypotension drug Northera should be approved for use in the United States.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer